Trial · NCT04612725
Adverse events96
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 96
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Double-blind Period: Benralizumab 30 mg Q4W | 5 | 59 | 5 |
| other | COVID-19 | Infections and infestations | Double-blind Period: Benralizumab 60 mg Q4W | 5 | 56 | 5 |
| other | COVID-19 | Infections and infestations | Double-blind Period: Placebo | 1 | 40 | 1 |
| other | COVID-19 | Infections and infestations | Extension Period: Benralizumab 30 mg Q4W | 4 | 49 | 4 |
| other | COVID-19 | Infections and infestations | Extension Period: Benralizumab 30 mg Q8W | 4 | 54 | 4 |
| other | COVID-19 | Infections and infestations | Extension Period: Placebo to Benralizumab | 5 | 37 | 5 |
| other | Nasopharyngitis | Infections and infestations | Double-blind Period: Benralizumab 30 mg Q4W | 1 | 59 | 2 |
| other | Nasopharyngitis | Infections and infestations | Double-blind Period: Benralizumab 60 mg Q4W | 4 | 56 | 4 |
| other | Nasopharyngitis | Infections and infestations | Double-blind Period: Placebo | 2 | 40 | 2 |
| other | Nasopharyngitis | Infections and infestations | Extension Period: Benralizumab 30 mg Q4W | 5 | 49 | 7 |
| other | Nasopharyngitis | Infections and infestations | Extension Period: Benralizumab 30 mg Q8W | 2 | 54 | 2 |
| other | Nasopharyngitis | Infections and infestations | Extension Period: Placebo to Benralizumab | 2 | 37 | 3 |
| other | Headache | Nervous system disorders | Double-blind Period: Benralizumab 30 mg Q4W | 3 | 59 | 3 |
| other | Headache | Nervous system disorders | Double-blind Period: Benralizumab 60 mg Q4W | 3 | 56 | 3 |
| other | Headache | Nervous system disorders | Double-blind Period: Placebo | 2 | 40 | 2 |
| other | Headache | Nervous system disorders | Extension Period: Benralizumab 30 mg Q4W | 2 | 49 | 2 |
| other | Headache | Nervous system disorders | Extension Period: Benralizumab 30 mg Q8W | 1 | 54 | 1 |
| other | Headache | Nervous system disorders | Extension Period: Placebo to Benralizumab | 1 | 37 | 1 |
| other | Sinusitis | Infections and infestations | Double-blind Period: Benralizumab 30 mg Q4W | 2 | 59 | 2 |
| other | Sinusitis | Infections and infestations | Double-blind Period: Benralizumab 60 mg Q4W | 0 | 56 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04612725/events